Aptorum Group Ltd Class A (APM) - Total Liabilities
Based on the latest financial reports, Aptorum Group Ltd Class A (APM) has total liabilities worth $4.90 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Aptorum Group Ltd Class A - Total Liabilities Trend (2016–2025)
This chart illustrates how Aptorum Group Ltd Class A's total liabilities have evolved over time, based on quarterly financial data. See Aptorum Group Ltd Class A short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Aptorum Group Ltd Class A Competitors by Total Liabilities
The table below lists competitors of Aptorum Group Ltd Class A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Silver Bull Resources Inc
TO:SVB
|
Canada | CA$8.59 Million |
|
Bioatla Inc
NASDAQ:BCAB
|
USA | $45.88 Million |
|
GEOTRANS S.A. ZY -10
F:5Z4
|
Germany | €4.08 Million |
|
Modern Times Group Mtg AB
ST:MTG-A
|
Sweden | Skr8.67 Billion |
|
Beauce Gold Fields Inc
V:BGF
|
Canada | CA$762.09K |
|
Digistar Corporation Bhd
KLSE:0029
|
Malaysia | RM225.61 Million |
|
Computer Forms (Malaysia) Bhd
KLSE:8044
|
Malaysia | RM5.92 Million |
|
K.C. Metalsheet Public Company Limited
BK:KCM
|
Thailand | ฿219.68 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Aptorum Group Ltd Class A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Aptorum Group Ltd Class A stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.78 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aptorum Group Ltd Class A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aptorum Group Ltd Class A (2016–2025)
The table below shows the annual total liabilities of Aptorum Group Ltd Class A from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $4.90 Million | +12.56% |
| 2024-12-31 | $4.35 Million | -17.19% |
| 2023-12-31 | $5.26 Million | -59.67% |
| 2022-12-31 | $13.03 Million | +196.15% |
| 2021-12-31 | $4.40 Million | -27.60% |
| 2020-12-31 | $6.08 Million | -33.22% |
| 2019-12-31 | $9.10 Million | -26.17% |
| 2018-12-31 | $12.33 Million | +826.46% |
| 2017-12-31 | $1.33 Million | +393.16% |
| 2016-12-31 | $269.84K | -- |
About Aptorum Group Ltd Class A
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small mol… Read more